In response to "A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system"

Annals of Neurology

Volumn 67, Issue 1, 2010, Pages 143-144

  Raybon, Joseph J ^a   Albright, Charles F ^b  

^a Pharmaceutical Candidate Optimization: Metabolism and Pharmacokinetics   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 13; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; PLACEBO;

CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; PRIORITY JOURNAL;

ALANINE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; AREA UNDER CURVE; AZEPINES; BIOMEDICAL RESEARCH; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; TIME FACTORS;

EID: 77649323568     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21929     Document Type: Letter

References (4)

1. Bateman RJ, Siemers ER, Mawuenyega KG, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009;66:48-54.
2. Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006;12:856-861.
3. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, 1982.
4. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666-669.